Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| CNTO1959PSA4001 | Other Identifier | Janssen Research & Development, LLC |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate treatment persistence with guselkumab and interleukin-17 inhibitor (IL-17i) initiated at enrollment into this study (PsABIOnd).
Psoriatic arthritis (PsA) is a seronegative inflammatory spondylarthritis associated with psoriasis (PsO), which can cause pain and swelling in the joints, sausage-shaped swelling of the fingers and toes (dactylitis), inflammation of the muscle- or tendon insertions at adjacent bone (enthesitis), as well as raised red patches or various other expressions of psoriasis on the skin. Guselkumab (TREMFYA) is a fully human immunoglobulin G1 lambda (IgG1) monoclonal antibody (mAb) that binds to the p19 subunit of human interleukin (IL) 23 with high specificity and affinity, blocking IL-23 binding. Binding of guselkumab to the IL-23p19 subunit blocks the subsequent binding of extracellular IL-23 to the cell surface IL-23 receptor, inhibiting IL-23 specific intracellular signaling and subsequent activation and cytokine production. Participants with confirmed diagnosis of PsA who are starting guselkumab or any marketed interleukin-17 inhibitor (IL-17i) as a first, second, third, or fourth line of PsA biologic therapy per standard clinical practice will be enrolled in the main study. The aim of main study is to document the use of guselkumab and approved IL-17i therapies in routine clinical practice in patients with PsA who are starting guselkumab or an IL-17i as a first, second, third, or fourth line of biologic disease-modifying antirheumatic drugs (bDMARD) therapy. The overall duration of the main study, including recruitment and follow-up, is expected to be about 6 years. Participants who are starting guselkumab or an IL-17i treatment per routine clinical practice in the main study, and who meet the selection criteria for both the main study and substudy, will be consecutively offered entry into the substudy (a select number) at the time of enrollment into the main study. The substudy aims to collect additional data, continuously or with increased frequency, on the impact of guselkumab or IL-17i on patient mood, physical activity, sleep disturbance, disease symptoms, and health-related quality-of-life (HRQoL). Total duration of the substudy will be approximately 26-30 weeks consisting of a pre-treatment period of up to 14 days before the first dose of guselkumab or IL-17i in the main study and a 24-week (plus [+] up to 4 weeks follow-up) observation period.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort 1: Guselkumab | Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of Psoriatic Arthritis (PsA) who are starting guselkumab as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study. |
| |
| Cohort 2: Interleukin-17 inhibitor (IL-17i) | Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of PsA who are starting IL-17i as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Guselkumab | Drug | Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with guselkumab, will be observed according to standard clinical practice. |
| Measure | Description | Time Frame |
|---|---|---|
| The Start and Stop Date of Guselkumab, as Applicable, For Each Participant | The start and stop date, (first and last administration date, respectively) of guselkumab, as applicable, for each participant will be collected to document treatment persistence. | Up to 39 months |
| The Start and Stop Date of Interleukin-17 Inhibitor (IL-17i), as Applicable, For Each Participant | The start and stop date (first and last administration date respectively) of IL-17i, as applicable, for each participant will be collected to document treatment persistence. | Up to 39 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change from Baseline in 66 and 68 Joint Counts for Swelling and Tenderness, Respectively | Change from baseline in 66 and 68 joint counts for swelling and tenderness, respectively will be reported. Joints assessed include the distal interphalangeal, proximal interphalangeal, and metacarpophalangeal joints of the hands; the wrist, elbow, shoulder, acromioclavicular, sternoclavicular, temporomandibular, hip (excluded for swelling), knee, ankle, and midtarsal joints; and the metatarsophalangeal and proximal interphalangeal joints of the feet. |
Not provided
Inclusion Criteria:
Main study:
Substudy:
Exclusion Criteria:
Main study:
Substudy:
Not provided
Not provided
Not provided
Not provided
The study population consists of participants initially treated for Psoriatic Arthritis (PsA) with guselkumab or interleukin-17 inhibitor (IL-17i) per routine clinical practice in accordance with clinical guidelines.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Janssen Pharmaceutica N.V., Belgium Clinical Trial | Janssen Pharmaceutica N.V., Belgium | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| OMI | Buenos Aires | C1015ABO | Argentina | |||
| Hospital Italiano de Buenos Aires |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36585602 | Derived | Siebert S, Behrens F, Lubrano E, Martin N, Sharaf M, Contre C, Theander E, Queiro R, Zimmermann M, Gossec L. PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis. Rheumatol Ther. 2023 Apr;10(2):489-505. doi: 10.1007/s40744-022-00518-w. Epub 2022 Dec 30. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| IL-17i | Drug | Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with IL-17i, will be observed according to standard clinical practice. |
|
| Baseline up to 39 months |
| Change from Baseline in Rheumatologist's Global Assessment of Disease Activity-Psoriatic Arthritis (PGA-PsA) | The PGA-PsA will be documented using a Visual Analogue Scale (VAS) that ranges from "no PsA activity" (0 Millimeter [mm]) to "extremely active PsA" (100 mm). | Baseline up to 39 months |
| Change from Baseline in Assessment of Dactylitis | The presence of and total number of digits of the hands and feet (that is, 0 to 20) with dactylitis will be documented. | Baseline up to 39 months |
| Change from Baseline in Assessment of Enthesitis using Leeds Enthesitis Index (LEI) | The presence and a score of enthesitis will be documented using the LEI to evaluate the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: the lateral epicondyles (left and right), medial femoral condyles (left and right), and Achilles tendon insertions (left and right). | Baseline up to 39 months |
| Change from Baseline in Nail Involvement | Nail involvement will be documented by recording the total number of nails of the hands and feet (that is, 0 to 20) with psoriatic nail changes. | Baseline up to 39 months |
| Change from Baseline in Body Surface Area (BSA) Psoriasis (PSO) Skin Involvement | The BSA score indicates the surface area of the participant's body effected by psoriasis. | Baseline up to 39 months |
| Change from Baseline in C-reactive Protein (CRP) | Change from baseline in CRP will be reported. | Baseline up to 39 months |
| Change from Baseline in Minimal Disease Activity (MDA)/ Very Low Disease Activity (VLDA) | Change from Baseline in MDA/VLDA will be reported. | Baseline up to 39 months |
| Change from Baseline in Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA/DAPSA) | DAPSA assesses the joint domain of PsA and is derived from the sum of the following components: Participant's assessment of pain on VAS (in centimeters), Participant's Global Assessment of Disease Activity on VAS (in centimeters), 66 and 68 joint counts for swelling and tenderness, respectively. | Baseline up to 39 months |
| Response as a Measure of Clinical Improvement in cDAPSA/DAPSA | Response is defined as a clinical improvement in cDAPSA/DAPSA. DAPSA assesses the joint domain of PsA and is derived from the sum of the following components: Participant's assessment of pain on VAS (in centimeters), Participant's Global Assessment of Disease Activity on VAS (in centimeters), 66 and 68 joint counts for swelling and tenderness, respectively. | Up to 39 months |
| Start and Stop Dates of All Treatments and the Sequence of Treatment Lines | Start and stop dates of all treatments and the sequence of treatment lines will be reported. | Up to 39 months |
| Percentage of Participants with Adverse Events (AEs) | An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. | Up to 39 months |
| BSA PSO Skin Involvement | The BSA score indicates the surface area of the participant's body affected by psoriasis. | Up to 39 months |
| Rheumatic Disease Comorbidity Index | Number of comorbid medical conditions of the study participants for the Rheumatic Disease Comorbidity Index will be reported. | Up to 39 months |
| Change from Baseline in Fibromyalgia Rapid Screening Tool (FiRST) | FiRST will be used to help determine whether participants have chronic widespread pain or fibromyalgia syndrome at entry into the study. The FiRST is a validated questionnaire consisting of a combination of 6 items that can detect chronic widespread pain. | Baseline up to 6 months |
| Change from Baseline in European Quality of Life (EuroQoL) 5-Dimensions 5-Levels Questionnaire (EQ-5D-5L) | The EQ-5D-5L is a standardized instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems, where Level 1: no problem, Level 2: slight problems, Level 3: moderate problems, Level 4: severe problems and Level 5: extreme problems. | Baseline up to 39 months |
| Change from Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) | The functional status of the participants will be assessed by the HAQ-DI. This 20-question self-administered instrument assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area. | Baseline up to 39 months |
| Change from Baseline in Psoriatic Arthritis Impact of Disease-12 (PsAID-12) | PsAID-12 is a validated, self-administered questionnaire that assesses the impact of PsA on participants' lives. It consists of 12 questions, each answered using a numerical rating scale. Questions related to pain, skin problems, work and/or leisure activities, discomfort, embarrassment and/or shame, social participation, and anger, fear, and uncertainty, and depression are scored from 0 (none) to 10 (extreme), functional capacity and sleep disturbance are scored from 0 (no difficulty) to 10 (extreme difficulty) and coping is scored from 0 (very well) to 10 (very poorly). | Baseline up to 39 months |
| Change from Baseline in Patient Global Disease Activity Visual Analog Scale (VAS) Scores | The Patient Global Disease Activity VAS is a self-administered assessment with scores ranging from "very well" (0 mm) to "very poor" (100 mm) that assesses disease activity over the past week. | Baseline up to 39 months |
| Change from Baseline in Pain VAS Score | The pain VAS is a self-administered assessment of average pain during the past week. The scale ranges from "no pain" (0 mm) to "the worst possible pain" (100 mm). | Baseline up to 39 months |
| Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) | BASDAI consists of a 1 through 10 scale (1 being no problem and 10 being the worst problem) which is used to answer 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain/swelling, areas of localized tenderness (also called enthesitis, or inflammation of tendons and ligaments), morning stiffness duration, morning stiffness severity. | Baseline up to 39 months |
| Change from Baseline in Ankylosing Spondylitis Disease Activity Score - C-reactive protein (ASDAS-CRP) | The ASDAS-CRP is a composite of 5 disease activity variables with only partial overlap. The 4 self-reported items included in this index are back pain (VAS), duration of morning stiffness, peripheral pain/swelling, and participant global assessment of disease activity; these are combined with the CRP value. | Baseline up to 39 months |
| Change from Baseline in Dermatology Life Quality Index (DLQI) | The DLQI is a dermatology-specific, validated, 10-question quality of life instrument used to measure the impact of skin disease on the quality of life of an affected person. Each question will address how much the participant's skin problem has affected their life and is scored as: 3 = very much, 2 = a lot, 1 = a little, 0 = not at all, or not relevant. | Baseline up to 39 months |
| Change from Baseline in Patient Acceptable Symptom State (PASS) | The PASS measures the level of symptoms beyond which participants consider themselves well. The PASS addresses the concepts of low disease activity, partial remission in symptoms, and well-being. | Baseline up to 39 months |
| Change from Baseline in Work Productivity and Activity Impairment Questionnaire: Psoriatic Arthritis (WPAI: PsA) | The WPAI: PsA is a validated, self-administered questionnaire that assesses work and activity impairment during the past 7 days. The WPAI: PsA produces 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment. The WPAI: PsA outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, that is, worse outcomes. | Baseline up to 39 months |
| Change from Baseline in Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) | TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness, convenience, and side effects of the medication. | Baseline up to 39 months |
| Number of Participants Switching or Stopping Treatment | Number of Participants switching or stopping treatment (including reasons for discontinuation) will be reported. | Up to 39 months |
| Buenos Aires |
| C1199ABB |
| Argentina |
| Hospital J. M. Ramos Mejía | Buenos Aires | C1221ADC | Argentina |
| Hospital Cordoba | Córdoba | 5000 | Argentina |
| MR Medicina Reumatologica | San Fernando | B1646 | Argentina |
| The Queen Elizabeth Hospital | Adelaide | 5011 | Australia |
| Footscray Hospital, Western Health | Footscray | Australia |
| Royal North Shore Hospital | St Leonards | 2065 | Australia |
| LKH-Univ. Klinikum Graz | Graz | 8036 | Austria |
| Kepler Universitatsklinikum GmbH | Linz | 4021 | Austria |
| Medizinische Universitaet Wien | Vienna | 1090 | Austria |
| Evang. Krankenhaus Gemein. Betriebgesm. Mbh | Vienna | A-1100 | Austria |
| AZ Sint-Jan | Bruges | 8000 | Belgium |
| Hopital Erasme | Brussels | 1070 | Belgium |
| Reumaclinic Genk-Hasselt | Genk | 3600 | Belgium |
| UZ Leuven | Leuven | 3000 | Belgium |
| CHU de Liège - Domaine Universitaire du Sart Tilman | Liège | 4000 | Belgium |
| Artus Health Centre | Vancouver | British Columbia | V5Z 1J9 | Canada |
| Manitoba Clinic | Winnipeg | Manitoba | R3A 1M3 | Canada |
| St. Claire's Mercy Hospital - Rheumatology Research | St. John's | Newfoundland and Labrador | A1C 5B8 | Canada |
| Dr. Juris Lazovskis Incorporated | Coxheath | Nova Scotia | B1L 1B3 | Canada |
| Private Practice - Dr. Pauline Boulos | Dundas | Ontario | L9H 1B7 | Canada |
| Markham Rheumatology Hub | Markham | Ontario | L3R 2C7 | Canada |
| Brandusa Florica Medicine Professional Corporation | Mississauga | Ontario | L5A 3V8 | Canada |
| The Waterside Clinic | Orillia | Ontario | L3V 1T5 | Canada |
| The Ottawa Hospital Research Institute | Ottawa | Ontario | K1H 7W9 | Canada |
| Dr Sabeen Anwar Medicine Professional Corporation | Windsor | Ontario | N8X 1T3 | Canada |
| CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont | Montreal | Quebec | H1T 2M4 | Canada |
| G R M O Groupe de recherche en maladies osseuses Inc | Québec | Quebec | G1V 3M7 | Canada |
| Centre de sante et services sociaux (CSSS) de Rimouski-Neigette - Hopital regional - Rimouski | Rimouski | Quebec | G5L 5T1 | Canada |
| Centre de Recherche Musculo Squelettique | Trois-Rivières | Quebec | G9A 3X2 | Canada |
| Community Rheumatology Care | Saskatoon | Saskatchewan | S7K 0H6 | Canada |
| Rheumatology Associates of Saskatoon | Saskatoon | Saskatchewan | S7K 0H6 | Canada |
| BIOMAB | Bogotá | Colombia |
| Servimed S A S | Bucaramanga | Colombia |
| Clinisalud del Sur | Medellín | 50012 | Colombia |
| Clinica Vascular las Americas | Medellín | 50025 | Colombia |
| Funcentra | Montería | 230002 | Colombia |
| Hôpital Avicenne | Bobigny | 93000 | France |
| Centre Hospitalier de Cholet | Cholet | 49300 | France |
| Hôpital Gabriel Montpied | Clermont-Ferrand | 63003 | France |
| Centre Hospitalier Universitaire(CHU) - Hopital Henri Mondor | Créteil | 94000 | France |
| CHU Grenoble | Échirolles | 38130 | France |
| CHRU HOPITAL ROGER SALENGRO Consultation Appareil locomoteur | Lille | 59037 | France |
| Centre Orthopedique Santy | Lyon | 69008 | France |
| Clinique de l'Infirmerie Protestante de Lyon | Lyon | 69300 | France |
| Hôpital Saint Roch | Nice | 6006 | France |
| CHR Orléans - Nouvel Hôpital Orléans La Source | Orléans | 45032 | France |
| Hôpital Lariboisière - Centre Viggo Petersen | Paris | 75010 | France |
| Hopital Saint-Antoine | Paris | 75012 | France |
| Hôpital Bichat | Paris | 75018 | France |
| Hopital Pitie Salpetriere | Paris | 75651 | France |
| CHRU Hôpital de Hautepierre | Strasbourg | 67098 | France |
| Hopital Purpan | Toulouse | 31059 | France |
| Praxis für Rheumatologie | Amberg | 92224 | Germany |
| Rheuma-Praxis Bayreuth | Bayreuth | 95444 | Germany |
| Rheumatologische Schwerpunktpraxis | Berlin | 12161 | Germany |
| Rheumatologische Schwerpunktpraxis 1 | Berlin | 13055 | Germany |
| Krankenhaus Porz am Rhein | Cologne | 51149 | Germany |
| Universitatsklinikum Dusseldorf | Düsseldorf | 40225 | Germany |
| Service Rheuma Erfurt | Erfurt | 99096 | Germany |
| Universitatsklinikum Frankfurt | Frankfurt | 60590 | Germany |
| Rheumapraxis Dr. Liebhaber | Halle | 6128 | Germany |
| Praxis fur Klinische Studien und Praxis fur Orthopadie | Hamburg | 22415 | Germany |
| Rheumatologie im Struenseehaus | Hamburg | 22767 | Germany |
| Rheumazentrum Ruhrgebiet | Herne | 44649 | Germany |
| Rheumatologische Praxis 1 | Leipzig | 04109 | Germany |
| Rheumatologische Praxis | Magdeburg | 39104 | Germany |
| Praxiszentrum St. Bonifatius | München | 81541 | Germany |
| Praxis Thilo Klopsch | Neubrandenburg | 17033 | Germany |
| Knappschaftsklinikum Saar GmbH Klinik für Rheumatologie | Püttlingen | 66346 | Germany |
| Rheumazentrum Ratingen | Ratingen | 40878 | Germany |
| Rheumatologisch-immunologische Arztpraxis | Templin | 17268 | Germany |
| Immunologisches Zentrum Vogelsang-Gommern GmbH | Vogelsang-Gommern | 39245 | Germany |
| Evangelismos General Hospital of Athens | Athens | 10676 | Greece |
| Athens Navy Hospital | Athens | 11521 | Greece |
| General Hospital 'Gennimatas' | Athens | 11527 | Greece |
| Hippokration General Hospital of Athens, B' Internal Medicine Clinic, | Athens | 11527 | Greece |
| Laiko General Hospital of Athens | Athens | 11527 | Greece |
| University Hospital of Ioannina | Ioannina | 45560 | Greece |
| 'Agios Andreas' General Hospital of Patras | Pátrai | 263 32 | Greece |
| University General Hospital of Rio Patras | Pátrai | 26500 | Greece |
| Ippokrateio Hospital | Thessaloniki | 546 42 | Greece |
| Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari | Bari | 70124 | Italy |
| Ospedale Regionale Cardarelli-Università degli Studi del Mol | Campobasso | 86100 | Italy |
| Universita della Magna grecia | Catanzaro | 88100 | Italy |
| AOU Careggi | Florence | 50141 | Italy |
| Azienda Ospedaliera Universitaria Federico II | Naples | 80131 | Italy |
| Seconda Univesità degli Studi di Napoli, AOU | Naples | 80131 | Italy |
| Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone | Palermo | 90127 | Italy |
| Azienda Ospedaliero Universitaria Pisana | Pisa | 56126 | Italy |
| Ospedale San Carlo Di Potenza - Azienda Ospedaliera Regionale | Potenza | 85100 | Italy |
| Universita Cattolica del Sacro Cuore | Rome | 20123 | Italy |
| Istituto Clinico Humanitas | Rozzano | 20156 | Italy |
| Azienda Ospedaliera Città della Salute e della Scienza di Torino | Torino | 10126 | Italy |
| Azienda Ospedaliero Universitaria S.Maria Della Misericordia | Udine | 33100 | Italy |
| Azienda Ospedaliera Universitaria Integrata Verona | Verona | 37067 | Italy |
| Kita-harima Medical Center | Hyōgo | 6751392 | Japan |
| Toho University Medical Center, Ohashi Hospital | Meguro-ku | 153-8515 | Japan |
| Osaka Metropolitan University Hospital | Osaka | 545 8586 | Japan |
| Public Interest Incorporated Foundation Nipoon Life Saiseikai Nippon Life Hospital | Osaka | 550 0006 | Japan |
| Hokkaido University Hospital | Sapporo | 060-8648 | Japan |
| Kyorin University Hospital | Tokyo | 181 8611 | Japan |
| Medical Care & Research SA de CV | Mérida | 97070 | Mexico |
| Consultorio de Reumatologia | México | 07760 | Mexico |
| Hospital Puerta de Hierro | Zapopan | 45116 | Mexico |
| Academisch Medisch Centrum Universiteit van Amsterdam | Amsterdam | 1105 AZ | Netherlands |
| Medisch Spectrum Twente | Enschede | 7500 KA | Netherlands |
| Universitair Medisch Centrum Groningen | Groningen | 9700 RB | Netherlands |
| Elkerliek Ziekenhuis | Helmond | 5707 HA | Netherlands |
| SBEU HPE Kemerovo State Medical Academy | Kemerovo | G4 0SF | Russia |
| Bakoulev Scientific Center For Cardiovascular Surgery Rams | Moscow | 121552 | Russia |
| FGBU Research Institute of Rheumatology named V.A.Nasonova | Moscow | 190068 | Russia |
| City Hospital #3 | Tomsk | 634045 | Russia |
| Soonchunhyang University Cheonan Hospital | Cheonan-si | 31151 | South Korea |
| Seoul National University Bundang Hospital | Seongnam | 13620 | South Korea |
| Seoul National University Hospital | Seoul | 03080 | South Korea |
| Seoul Metropolitan Government Seoul National University Boramae Medical Center | Seoul | 07061 | South Korea |
| Hosp Univ A Coruna | A Coruña | 15006 | Spain |
| Hosp. Punta de Europa | Algeciras / Cadiz | 11207 | Spain |
| Hosp Clinic de Barcelona | Barcelona | 08036 | Spain |
| Hosp Univ Vall D Hebron | Barcelona | 8035 | Spain |
| Hosp. Univ. de Basurto | Bilbao | 48013 | Spain |
| Hosp Reina Sofia | Córdoba | 14004 | Spain |
| Complejo hospitalario de Granada | Granada | 18016 | Spain |
| Hosp. Univ. 12 de Octubre | Madrid | 28041 | Spain |
| Hosp. Univ. de Getafe | Madrid | 28905 | Spain |
| Hosp. Univ. Central de Asturias | Oviedo | 33011 | Spain |
| Hosp. Clinico Univ. de Santiago | Santiago de Compostela | 15706 | Spain |
| Hosp. Virgen Del Rocio | Seville | 41013 | Spain |
| Sahlgrenska Universitetssjukhuset | Gothenburg | 41345 | Sweden |
| Universitetssjukhuset i Lund | Malmö | 20502 | Sweden |
| Universitetssjukhuset Orebro | Örebro | 70185 | Sweden |
| Akademiskt Specialistcentrum centrum för reumatologi | Stockholm | 113 65 | Sweden |
| Akademiska Sjukhuset | Uppsala | 75185 | Sweden |
| HFR Fribourg - Hôpital Cantonal | Fribourg | 1708 | Switzerland |
| Kaohsiung Veterans General Hospital | Kaohsiung City | 81362 | Taiwan |
| Chang Gung Medical Foundation | Kaohsiung City | 83301 | Taiwan |
| Taichung Veterans General Hospital | Taichung | Taiwan |
| NHS Grampian - Aberdeen Royal Infirmary (ARI) | Aberdeen | AB25 2ZB | United Kingdom |
| Nevill Hall Hospital | Abergavenny | NP7 7EG | United Kingdom |
| University Hospital Monklands | Airdrie | ML6 0JS | United Kingdom |
| Royal Free London NHS Foundation Trust Barnet Hospital | Barnet | EN5 3DJ | United Kingdom |
| Wolfson Centre Royal United Hospitals | Bath | BA1 3NG | United Kingdom |
| Glasgow Royal Infirmary | Glasgow | 650029 | United Kingdom |
| Hull Royal Infirmary | Hull | HU3 2JZ | United Kingdom |
| Leeds Teaching Hospitals NHS Trust Chapel Allerton Hospital | Leeds | LS7 4SA | United Kingdom |
| Central Manchester University Hospitals NHS Foundation Trust | Manchester | M13 9WL | United Kingdom |
| The Newcastle upon Tyne Hospitals NHS Trust - Freeman Hospit | Newcastle upon Tyne | NE7 7DN | United Kingdom |
| Queen Alexandra Hospital | Portsmouth | PO6 3LY | United Kingdom |
| Shirley Caldwell | Salford | M6 8HD | United Kingdom |
| Southampton General Hospital | Southampton | SO16 6YD | United Kingdom |
| Haywood Hospital | Staffordshire | ST6 7AG | United Kingdom |
| Stamford and Rutland hospital | Stamford | PE9 1UA | United Kingdom |
| Wishaw General | Wishaw | ML2 0DP | United Kingdom |
| ID | Term |
|---|---|
| D015535 | Arthritis, Psoriatic |
| ID | Term |
|---|---|
| D025242 | Spondylarthropathies |
| D025241 | Spondylarthritis |
| D013166 | Spondylitis |
| D013122 | Spinal Diseases |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D011565 | Psoriasis |
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000588857 | guselkumab |
Not provided
Not provided
Not provided